8-K: Neuronetics Reports Q4 and Full Year 2024 Results, Highlights Greenbrook Acquisition and Adolescent FDA Clearance

Neuronetics announces its fourth quarter and full year 2024 financial results, showcasing revenue growth driven by the acquisition of Greenbrook TMS and FDA clearance for adolescent depression treatment.

Summary

• Neuronetics reported an 11% increase in revenue for Q4 2024, reaching $22.5 million, and a 5% increase for the full year, totaling $74.9 million.
• The company acquired Greenbrook TMS on December 9, 2024, and received an additional $10 million in funding from Perceptive Advisors.
• U.S. NeuroStar Advanced Therapy System revenue was $3.8 million in Q4, while U.S. treatment session revenue reached $12.9 million.
• Greenbrook TMS revenue from December 10 to December 31, 2024, is included in the results, with U.S. clinic revenue at $4.4 million.
• The company achieved over 195,000 global patients treated with 7.1 million treatment sessions.
• Neuronetics expects total worldwide revenue between $28.0 million and $30.0 million for Q1 2025.
• For the full year 2025, the company anticipates total worldwide revenue between $145.0 million and $155.0 million, with a gross margin of approximately 55% and operating expenses between $90.0 million and $98.0 million.
• Neuronetics aims to achieve cash flow positive in Q3 2025.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting revenue growth, strategic acquisitions, and FDA clearances. However, it also acknowledges challenges such as decreased gross margins and net losses, resulting in a moderately positive sentiment.

Positives

• The acquisition of Greenbrook TMS expands Neuronetics' market presence and service offerings.
• FDA clearance for adolescent depression treatment broadens the addressable market by approximately 35% to 29.3 million patients.
• The company is on track to achieve $21 million in cost synergies from the Greenbrook acquisition.
• The Better Me Provider (BMP) program is showing positive results, with participants treating more patients than non-participants.
• The company completed a secondary offering of common stock raising approximately $18.9 million in net cash in February 2025.
• Neuronetics is the clear leader in TMS therapy, uniquely positioned to expand mental health access while delivering shareholder value through operational excellence and sustainable growth.

Negatives

• Gross margin for Q4 2024 decreased by 1,140 basis points to 66.2% due to the inclusion of Greenbrook's clinic business and reduction in treatment session revenue.
• Net loss for Q4 2024 was $(12.2) million, compared to $(5.4) million in Q4 2023.
• U.S. NeuroStar Advanced Therapy System revenue decreased by 15% in Q4 2024.
• Cash and cash equivalents decreased from $59.7 million as of December 31, 2023, to $18.5 million as of December 31, 2024.

Risks

• The company's ability to achieve or sustain profitable operations due to its history of losses.
• Reliance on the sale and use of the NeuroStar Advanced Therapy System to generate revenues.
• Availability of coverage and reimbursement from third-party payors for treatments using the company's products.
• Developments in competing technologies and therapies for the indications that the company's products treat.
• The company's ability to successfully roll out the company's Better Me Provider program on the planned timeline.
• The company's self-sustainability and existing cash balances.
• The company's ability to achieve cash flow positive in the third quarter of 2025.

Future Outlook

For Q1 2025, Neuronetics expects total worldwide revenue between $28.0 million and $30.0 million. For the full year 2025, the company expects total worldwide revenue to be between $145.0 million and $155.0 million, with a gross margin of approximately 55% and operating expenses between $90.0 million and $98.0 million. The company expects to achieve cash flow positive in Q3 2025.

Management Comments

• 2024 was a defining year for Neuronetics as we've strategically transformed our business model and market position, said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics.
• By expanding our Better Me Provider network and acquiring Greenbrook, we've created an unparalleled TMS treatment platform while rapidly improving our financial position.
• As we apply these proven methods across our expanded network and execute on our Greenbrook integration, we're building momentum toward our dual objectives of double-digit revenue growth for the year and becoming cash flow positive in Q3 2025.
• Neuronetics now stands as the clear leader in TMS therapy, uniquely positioned to expand mental health access while delivering shareholder value through operational excellence and sustainable growth.

Industry Context

The announcement reflects the ongoing consolidation in the mental health services industry, with Neuronetics' acquisition of Greenbrook TMS representing a significant move to create a larger, vertically integrated player in the TMS therapy market. The FDA clearance for adolescent depression also positions Neuronetics to capitalize on the growing demand for non-pharmacological treatments for mental health disorders.

Comparison to Industry Standards

• Neuronetics' acquisition of Greenbrook TMS is similar to other consolidation efforts in the healthcare services industry, such as Optum's acquisition of various physician groups and clinics.
• The company's focus on TMS therapy aligns with the broader trend of increasing adoption of non-invasive neuromodulation techniques for treating mental health disorders, competing with companies like MagVenture and Brainsway.
• The Better Me Provider program is similar to other value-based care initiatives in the healthcare industry, aiming to improve patient outcomes and reduce costs.
• Neuronetics' expansion into adolescent depression treatment mirrors the efforts of other pharmaceutical and medical device companies to address the unmet needs of this patient population.

Stakeholder Impact

• Shareholders: Potential for increased value through revenue growth, cost synergies, and profitability.
• Employees: Integration of Greenbrook TMS may lead to restructuring and changes in roles.
• Patients: Expanded access to TMS therapy and new treatment options for adolescent depression.
• Physicians: Opportunity to participate in the Better Me Provider program and improve patient outcomes.
• Suppliers: Potential for increased demand for NeuroStar systems and related products.

Next Steps

• Continue integration of Greenbrook TMS and realization of cost synergies.
• Expand the Better Me Provider network and implement the program across the broader network.
• Accelerate the SPRAVATO buy-and-bill expansion.
• Enhance capabilities to maintain the projected timeline to be cash flow positive in the third quarter of 2025.

Key Dates